Piroxicam |
Feldene |
Article: Piroxicam
![]() | |
| Piroxicam | |
| Systematic (IUPAC) name | |
| 9-(hydroxy-pyridin-2-ylamino-methylidene)- 8-methyl-7,7-dioxo-7$l^{6}-thia-8-azabicyclo[ 4.4.0] deca-1,3,5-trien-10-one | |
| Identifiers | |
| CAS number | 36322-90-4 |
| ATC code | M01AC01 M02AA07, S01BC06 |
| PubChem | 5280452 |
| DrugBank | APRD01187 |
| Chemical data | |
| Formula | C15H13N3O4S |
| Mol. weight | 331.348 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | 4-10% renal |
| Half life | 30 to 86 hours |
| Excretion | 4-10% renal |
| Therapeutic considerations | |
| Pregnancy cat. | C, D if used in the third trimester or near delivery |
| Legal status | |
| Routes | ? |
Piroxicam (US trade name Feldene) is a nonsteroidal anti-inflammatory drug used to relieve the symptoms of arthritis, primary dysmenorrhoea, pyrexia; and as an analgesic, especially where there is an inflammatory component. It is also used in veterinary medicine to treat certain neoplasias expressing cyclooxygenase (COX) receptors, such as bladder, colon, and prostate cancers.
Mechanism of action
Piroxicam is an NSAID and, as such, is a non-selective COX inhibitor.
Main article: Non-steroidal anti-inflammatory drug
Adverse effects
Piroxicam use can result in gastrointestinal toxicity, tinnitus, headache, and rash. The risk of adverse side effects is nearly ten times higher than with other NSAIDs.
Main article: Non-steroidal anti-inflammatory drug

Not Signed In - 

